FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076135213> ?p ?o ?g. }

• W2076135213 abstract "Telaprevir (TVR)-based triple therapy in patients (pts) with chronic hepatitis C (HCV) in daily practice in Germany is investigated in this non-interventional study. Aims are the evaluation of the implementation of futility rules, as well as safety and efficacy of TVR-based therapy. This prospective, multi-center study investigates TVR-based therapy in therapy-naïve and pretreated pts with genotype 1 chronic HCV in Germany, including pts with HIV co-infection. Patients are treated with a combination of TVR, ribavirin and peg-interferon. This interim analysis includes data from the first 100 pts (12.5% of the planned total) at 32 sites completing 12 weeks (W) of treatment. 66% of pts were pretreated for HCV. 36.4% of pts with pre-treatment were prior relapsers and 30.3% null or partial responders. Cirrhosis was present in 11% of all pts at baseline. HCV RNA levels below 800.000 IU/ml at baseline were present in 50% of pts. 67% of pts showed rapid virological response (RVR, undetectable HCV RNA at W4). Adherence to the futility rule (treatment stop if HCV-RNA>1000 IU/ml at W4) was 100% (N=9). At W12, 91.4% of pts had undetectable HCV RNA. 57.7% of therapy-naïve pts and 86.4% of previous relapsers were HCV-RNA negative at both W4 and 12 (70.8% in total). Only one patient achieving RVR at W4 suffered a virologic breakthrough. Nearly all pts (99%) had adverse events (AE) during the first 12W, 6% reported serious adverse events (SAE). AEs were mostly mild (63.9%) or moderate (34.6%) and frequently mentioned dry skin/pruritus (54%), gastrointestinal disorders (48%), anorectal discomfort (30%), rash (29%) and anemia (23%). Rash was mostly rated as mild or moderate (97.1%). An Hb decrease<12 g/dl (female) or<13 g/dl (male) was reported in 87% of pts. Mean Hb levels decreased from 14.8 g/dl at baseline to 10.6 g/dl at W12; Hb levels<8.5 g/dl at any time within the first 12W of treatment were present in 11% of anemia cases and 6.6% required transfusion. Only one patient received erythropoietin treatment. 2 cases each of anemia and rash were considered as SAE. These interim results suggest that TVR-based triple-therapy is efficient against GT1 chronic hepatitis C in a real life setting. Adherence to futility rules was confirmed in all patients. As observed in clinical trials, adverse events were reported frequently, including anemia and rash. As more data become available, results will be updated." @default.
• W2076135213 created "2016-06-24" @default.
• W2076135213 creator A5029234044 @default.
• W2076135213 creator A5029582159 @default.
• W2076135213 creator A5053593920 @default.
• W2076135213 creator A5068787709 @default.
• W2076135213 creator A5076739762 @default.
• W2076135213 creator A5079850830 @default.
• W2076135213 date "2012-11-11" @default.
• W2076135213 modified "2023-09-25" @default.
• W2076135213 title "Telaprevir-based triple-therapy in patients with chronic hepatitis C in Germany: a 12-week interim analysis of real-life data" @default.
• W2076135213 doi "https://doi.org/10.7448/ias.15.6.18424" @default.
• W2076135213 hasPublicationYear "2012" @default.
• W2076135213 type Work @default.
• W2076135213 sameAs 2076135213 @default.
• W2076135213 citedByCount "4" @default.
• W2076135213 countsByYear W20761352132013 @default.
• W2076135213 countsByYear W20761352132014 @default.
• W2076135213 crossrefType "journal-article" @default.
• W2076135213 hasAuthorship W2076135213A5029234044 @default.
• W2076135213 hasAuthorship W2076135213A5029582159 @default.
• W2076135213 hasAuthorship W2076135213A5053593920 @default.
• W2076135213 hasAuthorship W2076135213A5068787709 @default.
• W2076135213 hasAuthorship W2076135213A5076739762 @default.
• W2076135213 hasAuthorship W2076135213A5079850830 @default.
• W2076135213 hasBestOaLocation W20761352131 @default.
• W2076135213 hasConcept C126322002 @default.
• W2076135213 hasConcept C197934379 @default.
• W2076135213 hasConcept C203014093 @default.
• W2076135213 hasConcept C2522874641 @default.
• W2076135213 hasConcept C2776408679 @default.
• W2076135213 hasConcept C2776455275 @default.
• W2076135213 hasConcept C2776461080 @default.
• W2076135213 hasConcept C2776999253 @default.
• W2076135213 hasConcept C2778159067 @default.
• W2076135213 hasConcept C2780040827 @default.
• W2076135213 hasConcept C535046627 @default.
• W2076135213 hasConcept C61943457 @default.
• W2076135213 hasConcept C71924100 @default.
• W2076135213 hasConcept C90924648 @default.
• W2076135213 hasConceptScore W2076135213C126322002 @default.
• W2076135213 hasConceptScore W2076135213C197934379 @default.
• W2076135213 hasConceptScore W2076135213C203014093 @default.
• W2076135213 hasConceptScore W2076135213C2522874641 @default.
• W2076135213 hasConceptScore W2076135213C2776408679 @default.
• W2076135213 hasConceptScore W2076135213C2776455275 @default.
• W2076135213 hasConceptScore W2076135213C2776461080 @default.
• W2076135213 hasConceptScore W2076135213C2776999253 @default.
• W2076135213 hasConceptScore W2076135213C2778159067 @default.
• W2076135213 hasConceptScore W2076135213C2780040827 @default.
• W2076135213 hasConceptScore W2076135213C535046627 @default.
• W2076135213 hasConceptScore W2076135213C61943457 @default.
• W2076135213 hasConceptScore W2076135213C71924100 @default.
• W2076135213 hasConceptScore W2076135213C90924648 @default.
• W2076135213 hasIssue "6(Suppl 4)" @default.
• W2076135213 hasLocation W20761352131 @default.
• W2076135213 hasOpenAccess W2076135213 @default.
• W2076135213 hasPrimaryLocation W20761352131 @default.
• W2076135213 hasRelatedWork W180129732 @default.
• W2076135213 hasRelatedWork W1975576681 @default.
• W2076135213 hasRelatedWork W2021013463 @default.
• W2076135213 hasRelatedWork W2031877686 @default.
• W2076135213 hasRelatedWork W2060044480 @default.
• W2076135213 hasRelatedWork W2083588500 @default.
• W2076135213 hasRelatedWork W2089625154 @default.
• W2076135213 hasRelatedWork W2253270656 @default.
• W2076135213 hasRelatedWork W2548149772 @default.
• W2076135213 hasRelatedWork W2755121454 @default.
• W2076135213 hasVolume "15" @default.
• W2076135213 isParatext "false" @default.
• W2076135213 isRetracted "false" @default.
• W2076135213 magId "2076135213" @default.
• W2076135213 workType "article" @default.